INT54708

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 1994
Last Reported 2007
Negated 0
Speculated 1
Reported most in Body
Documents 22
Total Number 28
Disease Relevance 1.06
Pain Relevance 20.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Adrbk1) aging (Adrbk1) cytoplasm (Adrbk1)
Anatomy Link Frequency
neurons 5
NG108-15 3
brain 2
locus coeruleus 2
hippocampus 1
Adrbk1 (Rattus norvegicus)
Adrbk1 - K220R (2)
Pain Link Frequency Relevance Heat
withdrawal 20 99.92 Very High Very High Very High
cerebral cortex 17 99.84 Very High Very High Very High
Kinase C 473 99.68 Very High Very High Very High
mu opioid receptor 8 99.58 Very High Very High Very High
Locus ceruleus 9 99.52 Very High Very High Very High
Morphine 70 99.48 Very High Very High Very High
MU agonist 8 99.40 Very High Very High Very High
opioid receptor 51 99.28 Very High Very High Very High
agonist 676 99.24 Very High Very High Very High
Hippocampus 34 99.16 Very High Very High Very High
Disease Link Frequency Relevance Heat
Urological Neuroanatomy 7 93.92 High High
Generalized Anxiety Disorder 1 80.32 Quite High
Nash(non-alcoholic Steatohepatitis) 72 69.48 Quite High
Aids-related Complex 1 62.40 Quite High
Cancer 55 61.20 Quite High
Necrosis 5 60.64 Quite High
Anaplastic Astrocytoma 15 55.92 Quite High
Nociception 1 54.56 Quite High
Shock 11 43.68 Quite Low
Drug Induced Neurotoxicity 1 36.64 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Coexpression of the dominant-negative mutants GRK2-K220R, arrestin-2(319-418), dynamin I-K44A, rab5A-N133I or rab7-N125I partially prevented the decline in binding of the mutant after naloxone removal.
Spec (partially) Gene_expression (Coexpression) of GRK2 (K220R) associated with narcan
1) Confidence 0.75 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11641435 Disease Relevance 0 Pain Relevance 0.80
Acute and chronic morphine treatments and morphine withdrawal differentially regulate GRK2 and GRK5 gene expression in rat brain.
Gene_expression (expression) of GRK2 in brain associated with withdrawal and morphine
2) Confidence 0.75 Published 2002 Journal Neuropharmacology Section Title Doc Link 12384166 Disease Relevance 0.08 Pain Relevance 1.47
Chronic morphine treatment resulted in 30-70% down-regulation of GRK2 expression in cerebral cortex, hippocampus, thalamus, and locus coeruleus, opposite to what observed with the single morphine administration.
Gene_expression (expression) of GRK2 in hippocampus associated with locus ceruleus, thalamus, hippocampus, cerebral cortex and morphine
3) Confidence 0.75 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12384166 Disease Relevance 0.09 Pain Relevance 1.57
The current study investigated the potential regulatory effects of acute and chronic morphine administration and withdrawal on GRK2 and GRK5 gene expression in rat brain.
Gene_expression (expression) of GRK2 in brain associated with withdrawal and morphine
4) Confidence 0.75 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12384166 Disease Relevance 0.08 Pain Relevance 1.19
To investigate the functional role of G protein-coupled receptor kinases (GRK) in homologous desensitization of the mu-opioid receptor, human embryonic kidney (HEK) 293 cells, which express a significant level of GRK2, were stably transfected with the cDNA encoding the rat mu-opioid receptor.
Gene_expression (express) of GRK2 in embryonic kidney associated with opioid receptor
5) Confidence 0.69 Published 2000 Journal Neuropharmacology Section Abstract Doc Link 10698001 Disease Relevance 0 Pain Relevance 0.38
The proportion of GRK 2/3 in each fraction, relative to that of H, was: P2/H=0.11 and S2/H=0.45.
Gene_expression (proportion) of GRK 2
6) Confidence 0.65 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12527474 Disease Relevance 0.09 Pain Relevance 0.58
In D110A,K220RGRK2-transfected neurons the R2/R1 ratio difference was dramatically reduced indicating that inhibition of endogenous GRK2 attenuates M1 mACh receptor desensitization under all conditions, including those where the extent of receptor desensitization was increased by picrotoxin treatment (see Fig. 3e).
Gene_expression (transfected) of GRK2 in neurons
7) Confidence 0.65 Published 2007 Journal Journal of Neurochemistry Section Body Doc Link PMC2658029 Disease Relevance 0 Pain Relevance 0.10
mol/L) pre-treatment was also able to enhance the effect of D110A,K220RGRK2 expression, resulting in an almost complete blockade of M1 mACh receptor desensitization in picrotoxin-treated neurons (see Fig. 4e).
Gene_expression (expression) of GRK2 in neurons
8) Confidence 0.65 Published 2007 Journal Journal of Neurochemistry Section Body Doc Link PMC2658029 Disease Relevance 0 Pain Relevance 0.36
In addition, staurosporine did not alter the R2/R1 ratio in the presence of D110A,K220RGRK2 in spontaneously synaptically-active neurons.
Gene_expression (presence) of GRK2 in neurons
9) Confidence 0.65 Published 2007 Journal Journal of Neurochemistry Section Body Doc Link PMC2658029 Disease Relevance 0 Pain Relevance 0.35
The enhanced and prolonged desensitization of M1 mACh receptor signalling observed in picrotoxin- and agonist-treated cultures appears to depend on both GRK2 and PKC activities, as expression of the dominant-negative D110A,K220RGRK2 construct only partially ameliorated agonist-induced receptor desensitization and further amelioration was observed in the presence of either a PKC inhibitor, or following phorbol ester-induced down-regulation of PKC activities.
Gene_expression (expression) of GRK2 associated with kinase c and agonist
10) Confidence 0.65 Published 2007 Journal Journal of Neurochemistry Section Body Doc Link PMC2658029 Disease Relevance 0 Pain Relevance 0.31
When nimodipine was associated to the chronic opioid treatment, tolerance expression was prevented, and immunoreactivity levels of GRK2, GRK6 and beta-arrestin 2 recovered the control values.
Gene_expression (levels) of GRK2 associated with tolerance and opioid
11) Confidence 0.54 Published 2001 Journal J. Neurochem. Section Abstract Doc Link 11299311 Disease Relevance 0 Pain Relevance 1.22
Chronic morphine administration increases beta-adrenergic receptor kinase (beta ARK) levels in the rat locus coeruleus.
Gene_expression (levels) of beta-adrenergic receptor kinase in locus coeruleus associated with locus ceruleus and morphine
12) Confidence 0.49 Published 1994 Journal J. Neurochem. Section Title Doc Link 7931357 Disease Relevance 0 Pain Relevance 0.60
In hippocampal neurons over-expression of GRK2, or its kinase-dead mutant form, completely suppresses M1 mACh receptor-stimulated PLC signalling (Willets et al. 2004).
Gene_expression (expression) of GRK2 in neurons
13) Confidence 0.38 Published 2007 Journal Journal of Neurochemistry Section Body Doc Link PMC2658029 Disease Relevance 0 Pain Relevance 0.19
However, in relation to the latter, PKC has previously been shown to phosphorylate GRK2 resulting in enhanced desensitization of ?
Gene_expression (resulting) of GRK2 associated with kinase c
14) Confidence 0.38 Published 2007 Journal Journal of Neurochemistry Section Body Doc Link PMC2658029 Disease Relevance 0.07 Pain Relevance 0.38
Chronic morphine treatment resulted in 30-70% down-regulation of GRK2 expression in cerebral cortex, hippocampus, thalamus, and locus coeruleus, opposite to what observed with the single morphine administration.
Gene_expression (expression) of GRK2 in locus coeruleus associated with locus ceruleus, thalamus, hippocampus, cerebral cortex and morphine
15) Confidence 0.25 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12384166 Disease Relevance 0.09 Pain Relevance 1.57
Chronic morphine treatment resulted in 30-70% down-regulation of GRK2 expression in cerebral cortex, hippocampus, thalamus, and locus coeruleus, opposite to what observed with the single morphine administration.
Gene_expression (expression) of GRK2 in cerebral cortex associated with locus ceruleus, thalamus, hippocampus, cerebral cortex and morphine
16) Confidence 0.25 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12384166 Disease Relevance 0.09 Pain Relevance 1.57
Chronic morphine treatment resulted in 30-70% down-regulation of GRK2 expression in cerebral cortex, hippocampus, thalamus, and locus coeruleus, opposite to what observed with the single morphine administration.
Gene_expression (expression) of GRK2 in thalamus associated with locus ceruleus, thalamus, hippocampus, cerebral cortex and morphine
17) Confidence 0.25 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12384166 Disease Relevance 0.09 Pain Relevance 1.57
Wild-type GRK2 was stably expressed in NG108-15 cells, which endogenously express A2AR and A2BR.
Gene_expression (expressed) of GRK2 in NG108-15
18) Confidence 0.25 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2245999 Disease Relevance 0 Pain Relevance 0.16
The acute stimulation of adenylyl cyclase by activation of A2AR was markedly reduced in NG108-15 cells overexpressing wild-type GRK2.
Gene_expression (overexpressing) of GRK2 in NG108-15
19) Confidence 0.25 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2245999 Disease Relevance 0.12 Pain Relevance 0.22
In addition, stable transfection of a dominant negative GRK2(Lys220Arg) mutant in the NG108-15 cells reduced the NECA-induced (30 min, 100 ?
Gene_expression (transfection) of GRK2 (K220R) in NG108-15
20) Confidence 0.22 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2245999 Disease Relevance 0.06 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox